During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- Could microorganisms in poop help treat the deadliest form of skin cancer?on August 16, 2019 at 7:34 am
Immunotherapy drugs stimulate a person's immune system to attack and destroy cancer. While they can significantly improve survival outcomes in those with melanoma, they are only effective in 40 to ...
- Buy Merck Stock Because Its Immunotherapy Drug Is a Game-Changer, Analyst Sayson August 16, 2019 at 6:17 am
Keytruda is a so-called anti-PD(L)1 inhibitor, one of a class of new immunotherapy drugs that uses the patient’s own immune system to fight cancer, and has had a major impact on cancer treatments.
- XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTICon August 15, 2019 at 10:30 pm
XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTIC XDX-01, a novel, point-of-care pre-treatment diagnostic, has completed early ...
- Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trialon August 15, 2019 at 10:30 am
IRVINE, Calif., Aug. 14, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing ...
- Merck's Cancer Immunotherapy Keytruda Continues to Aid Growthon August 15, 2019 at 5:30 am
The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. Cancer therapies that target either PD-1 or PD-L1 can stop ...
- Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapyon August 15, 2019 at 4:49 am
SLATE is an investigational immunotherapy directed at shared tumor-specific neoantigens (TSNA) which are derived from driver mutations, functionally important gene alterations recurrently observed in ...
- 2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapyon August 14, 2019 at 11:00 pm
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective ...
- What is immunotherapy anyway? What you need to know about this exciting cancer treatmenton August 14, 2019 at 6:56 am
One of the most exciting advancements in cancer treatment in recent years is immunotherapy, which uses the body's own immune system to fight cancer. Many people became aware of immunotherapy when ...
- Better tools, better cancer immunotherapyon August 9, 2019 at 7:53 am
In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of ...
- Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunitieson August 9, 2019 at 5:30 am
LAWRENCEVILLE, N.J, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics ...
via Google News and Bing News